Keyphrases
Immunomodulator
100%
Autoimmune Diabetes Mellitus
100%
Linomide
100%
Non-insulin-dependent Diabetes Mellitus (NIDDM)
66%
Pancreatic Cells
50%
Autoimmune Process
33%
Lymphocytes
16%
Therapeutic Approaches
16%
Cell Function
16%
Disease Stage
16%
Therapeutic Modalities
16%
Autoimmunity
16%
Non-obese Diabetic
16%
New Onset
16%
Immunosuppression
16%
Autoimmune Disease
16%
Advanced Disease
16%
Non-obese Diabetic Mice
16%
Normal Glucose Tolerance
16%
Human Insulin
16%
Cell Mass
16%
Autoimmune Diabetes
16%
Critical Mass
16%
Immunomodulatory Drugs (IMiDs)
16%
Diabetic Model
16%
Quinoline-3-carboxamide
16%
Medicine and Dentistry
Diabetes Mellitus
100%
Immunomodulating Agent
100%
Autoimmune Diabetes
100%
Roquinimex
100%
Disease
42%
Insulin Dependent Diabetes Mellitus
42%
Autoimmunity
42%
Lymphocyte
14%
Clinical Study
14%
Diabetes
14%
Therapeutic Modality
14%
Glucose Tolerance
14%
Immunosuppressive Treatment
14%
Autoimmune Disease
14%
Diabetic Obesity
14%
Cell Function
14%
Ob/Ob Mouse
14%
Human Insulin
14%
Recombinant Human Insulin
14%
Carboxamide
14%
Immunomodulatory Drug
14%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetes Mellitus
100%
Immunomodulating Agent
100%
Roquinimex
100%
Disease
42%
Insulin Dependent Diabetes Mellitus
42%
Clinical Study
14%
Diabetic Obesity
14%
Autoimmune Disease
14%
Carboxamide
14%
Recombinant Human Insulin
14%
Human Insulin
14%
Nonobese Diabetic Mouse
14%
Immunology and Microbiology
Immunomodulating Drugs
100%
Autoimmune Diabetes
100%
Roquinimex
100%
Autoimmunity
42%
Cell Function
14%
Lymphocyte
14%
Autoimmune Disease
14%
Immunosuppression
14%
Nonobese Diabetic Mouse
14%
Immunomodulatory Drug
14%